Sexual Function in Men Undergoing Androgen Deprivation Therapy

Gryzinski, Gustavo M.; Fustok, Judy; Raheem, Omer; Bernie, H.L.

doi:10.1089/andro.2022.0002

Cited by 4 publications

(3 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several randomized controlled trials have consistently shown that cytoreductive prostate radiotherapy, especially when combined with androgen deprivation therapy (ADT), can result in erectile dysfunction for a significant portion of patients. The severity of sexual dysfunction may fluctuate, yet it tends to be more pronounced in patients receiving higher radiation doses and undergoing prolonged ADT durations [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy

Ayoub,

Zamzam,

Elsemary

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background The impact of prostate radiotherapy on patient-reported health-related quality of life (HRQoL) significantly influences the outcomes of metastatic prostate cancer. We measured and compared HRQoL of metastatic prostate cancer patients who received cytoreductive prostate radiotherapy. Methods Between November 23, 2020, and November 21, 2022, we recruited 70 metastatic prostate cancer patients at the Department of Clinical Oncology at Suez Canal University Hospital. Patients were eligible if they had synchronous and metachronous histopathological confirmed metastatic adenocarcinoma and an Eastern Cooperative Oncology Group performance status ≤ 2. Random allocation was performed for either definitive local radiotherapy concurrent with the standard androgen deprivation therapy (ADT) or to the standard ADT alone. Definitive radiotherapy was delivered conventionally (70 Gy/35 fractions) or through the hypofractionated regimen (55 Gy/20 fractions). Patients completed the comprehensive European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-PR25) at baseline, then at three-month intervals for one year. The primary endpoint was patient-reported HRQoL, with secondary endpoints including toxicity and radiographic progression-free survival (rPFS). Mean HRQoL scores between groups were compared using the independent samples t-test. Results We observed clinically significant improvements in urinary and bowel functions between baseline, 3-month, 6-month, and 12-month intervals after receiving definitive prostate radiotherapy. Patients in the radiotherapy group had significantly lower urinary symptoms scores than the control group. However, sexual activity and functioning showed significant deterioration. Conclusion Cytoreductive prostate radiotherapy in metastatic prostate cancer patients significantly improved urinary functioning, preserved bowel functioning but was associated with worsening of sexual functioning. Trial Registration This trial was registered on (27/04/2023) with pactr.samrc.ac.za, PACTR202305854600529, URL: https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=25510.

show abstract

Section: Discussionmentioning

confidence: 99%

Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy

Ayoub,

Zamzam,

Elsemary

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Other common sexual AEs include reduced sexual desire, inability to achieve orgasm, and reduced penile and testicular size. 32 The effects of these AEs on sexual health can be further compounded by body composition changes, such as gynecomastia, weight gain, centralization of body fat, and loss of lean muscle mass. Importantly, the effects of ADT on sexual health can persist even after discontinuation, especially when combined with localized PCa treatments.…”

Section: Bone Healthmentioning

confidence: 99%

A Proposal for the Comprehensive Care of Men on Androgen Deprivation Therapy: Recommendations From the Multidisciplinary Prostate Cancer 360 Working Group

Crawford,

Garnick,

Eckel

et al. 2024

Urology Practice

View full text Add to dashboard Cite

a co-lead of the Canadian Androgen Deprivation Therapy Educational program, receives financial support for the program in the form of unrestricted educational grants from a consortium of pharmaceutical industry sponsors, including Astellas, Bayer, Novartis, Pfizer, and Tolmar; has also received speaker honorarium from Tolmar and Bayer for talks on androgen depression therapy. M.T.R.: consultant: OPKO, Astellas, Urovant, Sunovion. L.M.W.: As a co-lead of the Canadian Androgen Deprivation Therapy Educational program, receives financial support for the program in the form of unrestricted educational grants from a consortium of pharmaceutical industry sponsors, including Astellas, Bayer, Novartis, Pfizer, and Tolmar; has also received speaker honorarium for talks on assessing and managing sexual health from Merck and Astra Zeneca.

show abstract

“…Understanding the primary factors impacting sexual function in men is challenging, given the multitude of psychological, environmental, and physiological aspects that influence sexual performance. Nevertheless, well-established evidence demonstrates a significant role for testosterone in influencing sexual drive and, as a result, low testosterone levels are linked to low libido and impaired erectile and orgasmic functions [44,45].…”

Section: Sexual Dysfunctionmentioning

confidence: 99%

Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood

Reiss,

Gulkarov,

Pinkhasov

et al. 2023

Medicina

View full text Add to dashboard Cite

Prostate cancer is the second leading cause of cancer death in men in the United States. Androgen deprivation therapy (ADT) is currently the primary treatment for metastatic prostate cancer, and some studies have shown that the use of anti-androgen drugs is related to a reduction in cognitive function, mood changes, diminished quality of life, dementia, and possibly Alzheimer’s disease. ADT has potential physiological effects such as a reduction in white matter integrity and a negative impact on hypothalamic functions due to the lowering of testosterone levels or the blockade of downstream androgen receptor signaling by first- and second-generation anti-androgen drugs. A comparative analysis of prostate cancer patients undergoing ADT and Alzheimer patients identified over 30 shared genes, illustrating common ground for the mechanistic underpinning of the symptomatology. The purpose of this review was to investigate the effects of ADT on cognitive function, mood, and quality of life, as well as to analyze the relationship between ADT and Alzheimer’s disease. The evaluation of prostate cancer patient cognitive ability via neurocognitive testing is described. Future studies should further explore the connection among cognitive deficits, mood disturbances, and the physiological changes that occur when hormonal balance is altered.

show abstract

Sexual Function in Men Undergoing Androgen Deprivation Therapy

Cited by 4 publications

References 64 publications

Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy

Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy

A Proposal for the Comprehensive Care of Men on Androgen Deprivation Therapy: Recommendations From the Multidisciplinary Prostate Cancer 360 Working Group

Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood

Contact Info

Product

Resources

About